Table 2 Clinic-pathological characteristics of the study population
Patient characteristics | N(%) |
|---|---|
Age at first diagnosis (years) | |
  ≤ 50 | 61 (42.66) |
  > 50 | 82 (57.34) |
Menses | |
 Premenopausal | 59(41.26) |
 Postmenopausal | 84(58.74) |
Body Mass Index (BMI) | |
  ≤ 23 | 69(48.25) |
  > 23 | 74(51.75) |
Estrogen Receptor (ER) (%) | |
  < 10 | 50(34.97) |
  ≥ 10 | 93(65.03) |
Progesterone Receptor (PR) (%) | |
  < 10 | 42(29.37) |
  ≥ 10 | 101(70.63) |
Ki-67 (%) | |
  < 30 | 35(24.48) |
  ≥ 30 & < 60 | 65(45.45) |
  ≥ 60 | 43(30.07) |
HER-2 statusA | |
 Negative | 84(58.74) |
 Positive | 59(41.26) |
Clinical Tumor stageB | |
 cT1-cT2 | 72(50.35) |
 cT3-cT4 | 71(49.65) |
Clinical Nodal statusB | |
 cN0 | 19(13.29) |
 cN1-3 | 124(86.71) |
Efficacy | |
 Non-pCR | 93(65.03) |
 pCR | 50(34.97) |